| Mrs Latoya Lorraine Ajileye, NP | |
|
3699 Cascade Rd Sw Ste B2, Atlanta, GA 30331-2163 | |
| (404) 691-7006 | |
| Not Available |
| Full Name | Mrs Latoya Lorraine Ajileye |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 3699 Cascade Rd Sw Ste B2, Atlanta, Georgia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386154540 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | RN273713 (Georgia) | Secondary |
| 363L00000X | Nurse Practitioner | RN273713 (Georgia) | Primary |
| Entity Name | Piedmont Medical Care Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912956046 PECOS PAC ID: 6002802220 Enrollment ID: O20040422001500 |
News Archive
Raptor Pharmaceutical Corp., today announced that the first patient has been dosed in its Phase 2 clinical trial of DR Cysteamine for the potential treatment of Huntington's Disease. The Phase 2 clinical trial is being conducted under a previously announced collaboration agreement with The Centre Hospitalier Universitaire d'Angers ("CHU d'Angers"), which has commenced enrolling patients at eight clinical sites throughout France.
Besides affecting the blood sugar levels, the substance Metformin, also has an impact on blood fat levels. This was elucidated by an interdisciplinary team of the German Center for Diabetes Research headed by Dr. Rui Wang-Sattler of the Helmholtz Zentrum München. Especially the harmful LDL cholesterol can be reduced.
The Sudden Cardiac Arrest Foundation announced today the first virtual affiliate of its National Survivor Network(TM) at the National Association of EMS Physicians annual conference.
BioMimetic Therapeutics, Inc. today announced that effective December 31, 2009, the Company amended and restated its manufacturing and supply agreement with Novartis Vaccines and Diagnostics, Inc. for the supply of bulk rhPDGF-BB to BioMimetic.
› Verified 7 days ago
| Entity Name | Openloop Healthcare Partners Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245820661 PECOS PAC ID: 2668871898 Enrollment ID: O20220118000948 |
News Archive
Raptor Pharmaceutical Corp., today announced that the first patient has been dosed in its Phase 2 clinical trial of DR Cysteamine for the potential treatment of Huntington's Disease. The Phase 2 clinical trial is being conducted under a previously announced collaboration agreement with The Centre Hospitalier Universitaire d'Angers ("CHU d'Angers"), which has commenced enrolling patients at eight clinical sites throughout France.
Besides affecting the blood sugar levels, the substance Metformin, also has an impact on blood fat levels. This was elucidated by an interdisciplinary team of the German Center for Diabetes Research headed by Dr. Rui Wang-Sattler of the Helmholtz Zentrum München. Especially the harmful LDL cholesterol can be reduced.
The Sudden Cardiac Arrest Foundation announced today the first virtual affiliate of its National Survivor Network(TM) at the National Association of EMS Physicians annual conference.
BioMimetic Therapeutics, Inc. today announced that effective December 31, 2009, the Company amended and restated its manufacturing and supply agreement with Novartis Vaccines and Diagnostics, Inc. for the supply of bulk rhPDGF-BB to BioMimetic.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Latoya Lorraine Ajileye, NP 901 Rice St Nw, Atlanta, GA 30318-4938 Ph: (404) 613-2266 | Mrs Latoya Lorraine Ajileye, NP 3699 Cascade Rd Sw Ste B2, Atlanta, GA 30331-2163 Ph: (404) 691-7006 |
News Archive
Raptor Pharmaceutical Corp., today announced that the first patient has been dosed in its Phase 2 clinical trial of DR Cysteamine for the potential treatment of Huntington's Disease. The Phase 2 clinical trial is being conducted under a previously announced collaboration agreement with The Centre Hospitalier Universitaire d'Angers ("CHU d'Angers"), which has commenced enrolling patients at eight clinical sites throughout France.
Besides affecting the blood sugar levels, the substance Metformin, also has an impact on blood fat levels. This was elucidated by an interdisciplinary team of the German Center for Diabetes Research headed by Dr. Rui Wang-Sattler of the Helmholtz Zentrum München. Especially the harmful LDL cholesterol can be reduced.
The Sudden Cardiac Arrest Foundation announced today the first virtual affiliate of its National Survivor Network(TM) at the National Association of EMS Physicians annual conference.
BioMimetic Therapeutics, Inc. today announced that effective December 31, 2009, the Company amended and restated its manufacturing and supply agreement with Novartis Vaccines and Diagnostics, Inc. for the supply of bulk rhPDGF-BB to BioMimetic.
› Verified 7 days ago